ATE519488T1 - Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten - Google Patents

Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten

Info

Publication number
ATE519488T1
ATE519488T1 AT05854156T AT05854156T ATE519488T1 AT E519488 T1 ATE519488 T1 AT E519488T1 AT 05854156 T AT05854156 T AT 05854156T AT 05854156 T AT05854156 T AT 05854156T AT E519488 T1 ATE519488 T1 AT E519488T1
Authority
AT
Austria
Prior art keywords
aminopyrazine
rho
glaucoma
analogue
kinase
Prior art date
Application number
AT05854156T
Other languages
English (en)
Inventor
Mark R Hellberg
Andrew Rusinko
Alan Henderson
Cheng Guo
Mark Hadden
Helene Decornez
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE519488T1 publication Critical patent/ATE519488T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05854156T 2004-12-27 2005-12-14 Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten ATE519488T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63938904P 2004-12-27 2004-12-27
PCT/US2005/045384 WO2006071548A2 (en) 2004-12-27 2005-12-14 Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases

Publications (1)

Publication Number Publication Date
ATE519488T1 true ATE519488T1 (de) 2011-08-15

Family

ID=36615388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05854156T ATE519488T1 (de) 2004-12-27 2005-12-14 Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten

Country Status (16)

Country Link
US (2) US20080269249A2 (de)
EP (1) EP1830853B1 (de)
JP (1) JP2008525453A (de)
KR (1) KR100994173B1 (de)
CN (1) CN101102773B (de)
AR (1) AR053110A1 (de)
AT (1) ATE519488T1 (de)
AU (1) AU2005322338B2 (de)
BR (1) BRPI0519508A2 (de)
CA (1) CA2590261C (de)
ES (1) ES2368338T3 (de)
MX (1) MX2007007797A (de)
PL (1) PL383491A1 (de)
TW (1) TW200633709A (de)
WO (1) WO2006071548A2 (de)
ZA (1) ZA200704959B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2354140A1 (de) * 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridine als Kinaseinhibitoren
MX2008008328A (es) * 2005-12-22 2008-09-15 Alcon Res Ltd (indazol-5-il)-pirazinas y (1,3-dihidro-indol-2-ona)-pirazinas para tratar enfermedades y condiciones mediadas con rho cinasa.
MX2008012658A (es) 2006-03-31 2008-12-16 Schering Corp Inhibidores de cinasa.
AU2007275221A1 (en) * 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
BRPI0717320A2 (pt) 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
US7825261B2 (en) * 2006-12-05 2010-11-02 National Taiwan University Indazole compounds
MX2009013213A (es) * 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
CA2743134A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
CN102741240B (zh) 2009-10-30 2015-05-06 詹森药业有限公司 用作δ阿片类受体调节剂的嘧啶化合物
EP2493863B1 (de) 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substitutierte pyrimidine als opioidrezeptormodulatoren
JP5770197B2 (ja) * 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ．ベー． デルタオピオイド受容体調節因子としてのピラジン
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CA2798760A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as inhibitors of atr kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2568984A1 (de) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Als art-kinasehemmer nützliche verbindungen
MX2013000103A (es) 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
EP2723747A1 (de) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Als art-kinasehemmer nützliche verbindungen
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN106496173A (zh) 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
WO2013049722A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN108685922A (zh) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2909202A1 (de) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Als atr-kinaseinhibitoren nützliche verbindungen
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
KR101504722B1 (ko) 2013-06-12 2015-03-24 한국화학연구원 카모로놀 화합물을 유효성분으로 포함하는 심혈관 질환의 예방 및 치료용 약학적 조성물
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
MX373102B (es) 2014-06-05 2020-04-17 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
GB201715410D0 (en) 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
WO2019119207A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289815T1 (de) * 1995-12-21 2005-03-15 Alcon Lab Inc Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
BR9711154A (pt) * 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
CA2307285C (en) * 1998-08-17 2009-03-31 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
EP1177796B1 (de) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen
US6348494B1 (en) * 2000-11-21 2002-02-19 American Home Products Corporation Ethers of o-desmethyl venlafaxine
WO2001068607A1 (en) * 2000-03-16 2001-09-20 Mitsubishi Pharma Corporation Amide compounds and use thereof
AU2001236006A1 (en) * 2000-03-31 2001-10-15 Mitsubishi Pharma Corporation Preventives/remedies for kidney diseases
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
BR0214309A (pt) 2001-11-21 2004-10-13 Upjohn Co Derivados aril-1,4-pirazina substituìdos
AU2002358390A1 (en) 2001-12-18 2003-06-30 Astrazeneca Ab Novel compounds
US7094789B2 (en) * 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
EP1554258A1 (de) * 2002-08-20 2005-07-20 Neurogen Corporation 5-substituierte 2-arylpyrazine als modulatoren von crf-rezeptoren
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
JP2006521357A (ja) * 2003-03-24 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
CA2543644A1 (en) * 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
US20080194574A1 (en) * 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
WO2005095384A1 (en) * 2004-04-01 2005-10-13 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists

Also Published As

Publication number Publication date
CA2590261C (en) 2011-08-16
EP1830853B1 (de) 2011-08-10
PL383491A1 (pl) 2008-03-17
KR20070100952A (ko) 2007-10-15
BRPI0519508A2 (pt) 2009-03-17
AR053110A1 (es) 2007-04-25
EP1830853A2 (de) 2007-09-12
CA2590261A1 (en) 2006-07-06
CN101102773A (zh) 2008-01-09
AU2005322338A1 (en) 2006-07-06
MX2007007797A (es) 2007-08-23
ES2368338T3 (es) 2011-11-16
KR100994173B1 (ko) 2010-11-15
US20100216777A1 (en) 2010-08-26
WO2006071548A2 (en) 2006-07-06
JP2008525453A (ja) 2008-07-17
TW200633709A (en) 2006-10-01
ZA200704959B (en) 2009-04-29
WO2006071548A3 (en) 2006-09-08
US20060142307A1 (en) 2006-06-29
HK1104222A1 (en) 2008-01-11
US20080269249A2 (en) 2008-10-30
CN101102773B (zh) 2010-10-27
AU2005322338B2 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE494279T1 (de) Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate
EP1851237A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von knochenerkrankungen
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
EP1572075A4 (de) Verfahren zur behandlung von krankheiten in verbindung mit abnormaler kinasewirkung
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
EP2141989A4 (de) Zusammensetzungen und verfahren zur vorbeugung und behandlung von suchtkrankheiten
EP1732484A4 (de) Ophthalmisches implantat zur behandlung von glaukom
ATE551100T1 (de) Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
EP1804761A4 (de) Zusammensetzungen und verfahren zur behandlung von hautverfärbungen
DE602005017636D1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
EP1742675A4 (de) Behandlung von biomedizinischem abfall
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties